Triple Negative Breast Cancer - O'Regan

What are quantum dots? Explain their significance in breast cancer treatmentПодробнее

I am BRCA positive with breast cancer. Is there a particular chemotherapy that will benefit me?Подробнее

Why is immunotherapy not being used in patients with hormone receptor positive breast cancer?Подробнее

Education Session: Treatment Post CDK 4/6 InhibitorsПодробнее

Management for residual disease in TNBC after Chemo-ImmunotherapyПодробнее

TC vs ddAC-T in early triple-negative breast cancer.Подробнее

Breast Cancer Breakthroughs Episode 8: Navigating Breast Cancer RecurrenceПодробнее

Is race and ethnicity prognostic for breast cancer survival and outcomes?Подробнее

Daily Thoughts: Understanding Prevalence of Triple Negative Breast Cancer in Black WomenПодробнее

Patient Success Stories: Triple Negative Metastatic Breast Cancer, Ruth O’Regan MDПодробнее

Immune Checkpoint Inhibitors, Androgen Receptors, Targeted Agents and Personalized MedicineПодробнее

Dr. O’Regan on Biosimilar Education in Breast CancerПодробнее

New & Supporting Data for Optimizing Therapy in HER2+ Breast Cancer | Dr. Kaklamani and Dr. O’ReganПодробнее

Dr. O’Regan on Prognostic Value of pCR in HER2+ Breast CancerПодробнее

How to Treat Triple Negative Breast Cancer | Dr. Ruth O'Regan Chair & Dr. Anna WeissПодробнее

Dr. O'Regan on Future of Chemotherapy in Breast CancerПодробнее

Adjuvant CDK4/6 inhibition in early-stage HR-positive breast cancer | Ruth O'ReganПодробнее

Latest on Immunotherapy in Triple-Negative Breast Cancer - Medpage TodayПодробнее

11/19/2020: Triple Negative Breast Cancer: The Elusive Search for TargetsПодробнее

Dr. O’Regan on the Utility of CDK4/6 Inhibitors in Breast CancerПодробнее